Tigen exercises licensing option with the Ludwig Institute for Cancer Research, CHUV and University of Lausanne (UNIL) for the development of a Neoantigen-specific Tumor Infiltrating Lymphocytes product (NeoTIL)
- The executed license covers the development and future exclusive worldwide commercialization of NeoTIL, a Neoantigen-specific Tumor Infiltrating Lymphocytes (TIL) product.
- The signing of this option follows the existing Option, Collaboration and License Agreement that covers the Neoantigen-specific T cell Program at the CHUV on behalf of the Ludwig Institute.
Tigen has exercised an option to further develop and commercialize the Neo-Antigen T Cell Product from the Ludwig Institute, the CHUV and UNIL, that is currently in a Phase I trial for the treatment of solid tumors under the sponsorship of the CHUV in Lausanne (CHUV-DO-0018-NeoTIL-2019 / NCT04643574).
Under the terms of the option letter, the collaboration will be intensified around technical and clinical development to accelerate the program to move to the next stage of development.